Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaginal insert aims to clear persistent HPV in women

NCT ID NCT06491446

Ongoing Disease control Sponsor: Antiva Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental vaginal insert (ABI-2280) to see if it can safely clear persistent high-risk human papillomavirus (HPV) infection in women aged 25 to 55. Participants must have had HPV for at least a year with no serious cervical changes. The study compares different doses against a placebo to check safety and how well the virus is cleared.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection sexually transmitted disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMAVIRUS INFECTION

Contacts and locations

Locations

  • Arke Estudios Clinicos S.A. De C.V.

    Cuauhtémoc, CP 06700, Mexico

  • AusTrials Taringa

    Taringa, Australia

  • AusTrials Wellers Hill

    Tarragindi, Australia

  • Centro Oncologico Internacional

    Mexico City, CP 04700, Mexico

  • Clinical Horizons New Zealand

    Tauranga, New Zealand

  • Emeritus Research Camberwell

    Camberwell, Australia

  • Emeritus Research Sydney

    Sydney, Australia

  • FAICIC S. de R.L. de C.V.

    Veracruz, CP 91900, Mexico

  • Holdsworth House Medical Practice

    Darlinghurst, Australia

  • International Cancer Institute

    Eldoret, 8088-30100, Kenya

  • KIMR

    Nedlands, Australia

  • Kenya Medical Research Institute (KEMRI) - RCTP Kisumu

    Kisumu, 614-40100, Kenya

  • Lakeland Clinical Trials

    Rotorua, New Zealand

  • P3 Research Dunedin

    Dunedin, New Zealand

  • P3 Research Hawke's Bay

    Hastings, New Zealand

  • P3 Research Kapiti

    Paraparaumu, New Zealand

  • P3 Research Lower Hutt

    Lower Hutt, New Zealand

  • PARC Clinical Research, Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Pacific Clinical Trials Network - Tasman

    Nelson, New Zealand

  • The Royal Women's Hospital

    Parkville, Australia

  • Unidad de Medicina Especializada SMA

    Querétaro, CP 76800, Mexico

  • Victoria Biomedical Research Institute

    Kisumu, 7180-40100, Kenya

  • Victoria Cancer Care & Research Centres

    Kisii, 1376-40500, Kenya

  • Waitemata Clinical Research Ltd

    Birkenhead, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.